| Prev Close | 226.87 |
| Open | 227.30 |
| Day Low/High | 225.59 / 230.21 |
| 52 Wk Low/High | 197.47 / 306.08 |
| Volume | 940.19K |
Vertex Pharmaceuticals Incorporated (VRTX)
228.32
1.45
0.64
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 260.04B |
| Market Cap | 58.95B |
| P/E Ratio | 22.20 |
| Div & Yield | N.A. (N.A) |
The Next Big Thing in Biotech: Earnings
Adam Feuerstein, senior columnist for TheStreet, says biotech earnings are the next big thing to watch in biotech.
A Market in Limbo
Traders are jockeying for position as we await the Fed, economic data and key earnings.
The Next Big Thing in Biotech: Dendreon/Vertex Earnings
Senior columnist Adam Feuerstein says earnings from Dendreon and Vertex are the next big things in biotech.
The Next Big Thing In Biotech: Vertex
Adam Feuerstein, Sr. Columnist for TheStreet, says Vertex Pharmaceuticals is the next big thing in biotech.
The 5 Dumbest Things on Wall Street: June 1
Here is this week's roundup of the dumbest actions on Wall Street.
Slow, but Positive
The longer this action persists, the more anxious folks will be to put idle cash to work.
Biotech Breakout
SPDR S&P Biotech ETF is likely to post new highs in the second quarter.
Daily Recap of the Charts, May 7
Evan Lazarus of T3Live review the day's market action and sets up your trading plan for the next session.
The Next Big Thing in Biotech: Pfizer
Senior columnist Adam Feuerstein says Pfizer is the next big thing in biotech.
Looking for a Blaze of Markups
Here are a couple of window-dressing plays as we head into the end of the quarter.
Be Ready for Surprises
Earnings season is well upon us, so better to be prepared than, well, taken by surprise.
Divining the Earnings Winners
Based on patterns of estimates revisions, these names might just generate some magic when they report.
